

Natasha Rekhtman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/383426/publications.pdf>

Version: 2024-02-01

143
papers

23,691
citations

25034

57
h-index

11308

136
g-index

146
all docs

146
docs citations

146
times ranked

26271
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	12.6	6,756
2	Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2013, 19, 2240-2247.	7.0	2,097
3	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	1.6	1,109
4	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	16.8	827
5	In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. <i>Nature</i> , 2014, 516, 423-427.	27.8	538
6	Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping. <i>Cancer Discovery</i> , 2015, 5, 842-849.	9.4	514
7	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	9.4	490
8	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. <i>Journal of Thoracic Oncology</i> , 2022, 17, 362-387.	1.1	429
9	Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. <i>Cancer Cell</i> , 2017, 31, 286-299.	16.8	370
10	EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 220-229.	4.1	367
11	Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2016, 17, 1653-1660.	10.7	365
12	Neuroendocrine Tumors of the Lung: An Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 1628-1638.	2.5	355
13	p40 (p63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. <i>Modern Pathology</i> , 2012, 25, 405-415.	5.5	343
14	Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR, KRAS and Presence of PIK3CA, AKT1 Mutations. <i>Clinical Cancer Research</i> , 2012, 18, 1167-1176.	7.0	342
15	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. <i>Clinical Cancer Research</i> , 2016, 22, 3618-3629.	7.0	342
16	Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. <i>Modern Pathology</i> , 2011, 24, 1348-1359.	5.5	299
17	Regenerative lineages and immune-mediated pruning in lung cancer metastasis. <i>Nature Medicine</i> , 2020, 26, 259-269.	30.7	274
18	PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 523-535.	7.0	252

#	ARTICLE	IF	CITATIONS
19	Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3673-3679.	1.6	251
20	SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1823-1835.	1.1	234
21	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1599-1610.	1.1	234
22	Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at Risk for Histologic Transformation and Inferior Clinical Outcomes. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1784-1793.	1.1	232
23	Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing. <i>Journal of Thoracic Oncology</i> , 2011, 6, 451-458.	1.1	230
24	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2654-2663.	7.0	230
25	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 377-407.	1.1	212
26	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. <i>Cancer Cell</i> , 2020, 38, 229-246.e13.	16.8	210
27	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	1.1	182
28	Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. <i>Lancet Oncology</i> , 2012, 13, e418-e426.	10.7	178
29	Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology: A Paradigm Shift. <i>Journal of Thoracic Oncology</i> , 2010, 5, 411-414.	1.1	172
30	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. <i>Journal of Thoracic Oncology</i> , 2020, 15, 231-247.	1.1	172
31	MET-dependent solid tumours – molecular diagnosis and targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 569-587.	27.6	165
32	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	1.1	156
33	Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. <i>Cancer Cell</i> , 2021, 39, 1479-1496.e18.	16.8	155
34	Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score-Matched Analysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, 87-98.	1.1	153
35	Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. <i>Cancer Discovery</i> , 2018, 8, 686-695.	9.4	149
36	Pathological Diagnosis and Classification of Lung Cancer in Small Biopsies and Cytology: Strategic Management of Tissue for Molecular Testing. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 022-031.	2.1	140

#	ARTICLE	IF	CITATIONS
37	An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4880-4889.	7.0	140
38	Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 223-234.	1.1	134
39	The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5701-5708.	7.0	133
40	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. <i>Cancer Discovery</i> , 2015, 5, 610-621.	9.4	129
41	Using frozen section to identify histological patterns in stage I lung adenocarcinoma of accuracy and interobserver agreement. <i>Histopathology</i> , 2015, 66, 922-938.	2.9	127
42	p63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, Sparing-Material Approach. <i>Journal of Thoracic Oncology</i> , 2012, 7, 281-290.	1.1	126
43	Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1849-1856.	1.1	121
44	Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. <i>Cell Reports</i> , 2020, 33, 108444.	6.4	118
45	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. <i>Clinical Lung Cancer</i> , 2016, 17, e121-e129.	2.6	116
46	Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes. <i>Journal of Thoracic Oncology</i> , 2014, 9, 892-896.	1.1	106
47	KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. <i>Modern Pathology</i> , 2013, 26, 1307-1319.	5.5	102
48	Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. <i>Modern Pathology</i> , 2013, 26, 511-522.	5.5	95
49	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1267-1272.	2.5	95
50	Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with immunohistochemical and viral RNA studies. <i>Histopathology</i> , 2020, 77, 915-925.	2.9	92
51	Bronchiolar Adenoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1010-1026.	3.7	91
52	Immunocytochemistry for predictive biomarker testing in lung cancer cytology. <i>Cancer Cytopathology</i> , 2019, 127, 325-339.	2.4	78
53	Lung neuroendocrine neoplasms: recent progress and persistent challenges. <i>Modern Pathology</i> , 2022, 35, 36-50.	5.5	74
54	Cribriform and fused glands are patterns of high-grade pulmonary adenocarcinoma. <i>Human Pathology</i> , 2014, 45, 213-220.	2.0	73

#	ARTICLE	IF	CITATIONS
55	Immunophenotype and Response to Immunotherapy of <i>RET</i> -Rearranged Lung Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	3.0	73
56	Optimizing Workflows and Processing of Cytologic Samples for Comprehensive Analysis by Next-Generation Sequencing: Memorial Sloan Kettering Cancer Center Experience. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1200-1205.	2.5	72
57	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. <i>Clinical Cancer Research</i> , 2019, 25, 7113-7125.	7.0	69
58	Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. <i>Cancer Discovery</i> , 2021, 11, 3028-3047.	9.4	66
59	Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1170-1180.	3.7	61
60	Acquired <i>ALK</i> and <i>RET</i> Gene Fusions as Mechanisms of Resistance to Osimertinib in <i>EGFR</i> -Mutant Lung Cancers. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	3.0	60
61	Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. <i>Modern Pathology</i> , 2019, 32, 1106-1122.	5.5	58
62	Standardized terminology and nomenclature for respiratory cytology: The International Society of Cytopathology guidelines. <i>Diagnostic Cytopathology</i> , 2016, 44, 399-409.	1.0	57
63	Progenitor stem cell marker expression by pulmonary carcinomas. <i>Modern Pathology</i> , 2010, 23, 889-895.	5.5	56
64	Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1583-1593.	1.1	55
65	Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2020, 15, 589-600.	1.1	55
66	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. <i>PLoS ONE</i> , 2017, 12, e0182665.	2.5	54
67	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. <i>JAMA Surgery</i> , 2021, 156, e205601.	4.3	52
68	Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. <i>Modern Pathology</i> , 2018, 31, 111-121.	5.5	50
69	<i>Smarca4</i> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. <i>Cancer Discovery</i> , 2022, 12, 562-585.	9.4	48
70	<i>ALK</i> -Rearranged Lung Cancer: Adenosquamous Lung Cancer Masquerading as Pure Squamous Carcinoma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 768-769.	1.1	47
71	Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids. <i>Cancer Research</i> , 2019, 79, 4339-4347.	0.9	47
72	The evolution of <i>RET</i> inhibitor resistance in <i>RET</i> -driven lung and thyroid cancers. <i>Nature Communications</i> , 2022, 13, 1450.	12.8	47

#	ARTICLE	IF	CITATIONS
73	Response to Erlotinib in Patients with <i>EGFR</i> Mutant Advanced Non-Small Cell Lung Cancers with a Squamous or Squamous-like Component. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2535-2540.	4.1	46
74	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e435-e444.	2.6	46
75	Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. <i>Clinical Cancer Research</i> , 2021, 27, 4066-4076.	7.0	45
76	Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. <i>Lung Cancer</i> , 2017, 108, 205-211.	2.0	42
77	A Performance Comparison of Commonly Used Assays to Detect RET Fusions. <i>Clinical Cancer Research</i> , 2021, 27, 1316-1328.	7.0	39
78	Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients. <i>Lung Cancer</i> , 2018, 119, 85-90.	2.0	38
79	Cytology Specimens: A Goldmine for Molecular Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1189-1190.	2.5	35
80	Expansion of the Concept of Micropapillary Adenocarcinoma to Include a Newly Recognized Filigree Pattern as Well as the Classical Pattern Based on 1468 Stage I Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1948-1961.	1.1	35
81	<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 799-806.	7.0	35
82	Advances in Fine Needle Aspiration Cytology for the Diagnosis of Pulmonary Carcinoma. <i>Pathology Research International</i> , 2011, 2011, 1-7.	1.4	33
83	Predicting pulmonary adenocarcinoma outcome based on a cytology grading system. <i>Cancer Cytopathology</i> , 2012, 120, 35-43.	2.4	32
84	Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis. <i>Translational Lung Cancer Research</i> , 2020, 9, 860-878.	2.8	31
85	Novel Modification of HistoGel-Based Cell Block Preparation Method: Improved Sufficiency for Molecular Studies. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 529-535.	2.5	30
86	Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 7475-7484.	7.0	30
87	POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1109-1121.	1.1	29
88	CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes. <i>Radiology</i> , 2022, 303, 664-672.	7.3	28
89	Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 5-12.	1.2	26
90	Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 170.	17.0	26

#	ARTICLE	IF	CITATIONS
91	Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. <i>Clinical Cancer Research</i> , 2022, 28, 4702-4713.	7.0	25
92	MET inhibitor resistance in patients with MET exon 14-altered lung cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9006-9006.	1.6	24
93	Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003665.	1.2	23
94	Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma. <i>Modern Pathology</i> , 2020, 33, 2244-2255.	5.5	23
95	Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1188-1199.	1.1	23
96	Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1116-1120.	2.5	22
97	Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9028-9028.	1.6	22
98	CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki67 clone 30 is not susceptible to the inhibition: Critical diagnostic implications. <i>Cancer Cytopathology</i> , 2019, 127, 643-649.	2.4	21
99	Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1125-1127.	1.1	21
100	Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. <i>Nature Communications</i> , 2021, 12, 4789.	12.8	21
101	Multiplex testing for driver mutations in squamous cell carcinomas of the lung.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7505-7505.	1.6	21
102	Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. <i>Journal of Oncology Practice</i> , 2015, 11, 135-136.	2.5	20
103	Bronchiolar Adenoma/Pulmonary Ciliated Muconodular Papillary Tumor. <i>American Journal of Clinical Pathology</i> , 2021, 155, 832-844.	0.7	20
104	Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 253-259.	2.0	19
105	Rapid EGFR Mutation Detection Using the Idylla Platform. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 310-322.	2.8	19
106	Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1149-1165.	1.1	18
107	Ultraprapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100077.	1.1	18
108	Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. <i>Nature Communications</i> , 2022, 13, 2144.	12.8	18

#	ARTICLE	IF	CITATIONS
109	CNS Metastases in Patients With MET Exon 14 Altered Lung Cancers and Outcomes With Crizotinib. <i>JCO Precision Oncology</i> , 2020, 4, 871-876.	3.0	14
110	Spread Through Air Spaces (STAS) in Non-Small Cell Lung Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1509-1515.	3.7	14
111	An update on touch preparations of small biopsies. <i>Journal of the American Society of Cytopathology</i> , 2020, 9, 322-331.	0.5	14
112	Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms. <i>Cancer Cytopathology</i> , 2017, 125, 188-196.	2.4	13
113	Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 515-528.	2.8	12
114	Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics. <i>Analytical Cellular Pathology</i> , 2018, 2018, 1-7.	1.4	11
115	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100187.	1.1	11
116	Nonspecific Reactivity of Polyclonal Napsin A Antibody in Mucinous Adenocarcinomas of Various Sites: A Word of Caution. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 434-436.	2.5	10
117	Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1537-1548.	2.5	9
118	Pulmonary sclerosing pneumocytoma: Cytomorphology and immunoprofile. <i>Cancer Cytopathology</i> , 2020, 128, 414-423.	2.4	8
119	The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3656.	3.7	8
120	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	6.4	8
121	Percutaneous computed tomography guided biopsy of sub-solid pulmonary nodules: differentiating solid from ground glass components at the time of biopsy. <i>Clinical Imaging</i> , 2021, 69, 332-338.	1.5	7
122	Unsuspected Collision of Synchronous Lung Adenocarcinomas: A Potential Cause of Aberrant Driver Mutation Profiles. <i>Journal of Thoracic Oncology</i> , 2014, 9, e1-e3.	1.1	6
123	Spread Through Air Spaces Is Prognostic in Neuroendocrine Lung Tumors and Can Be Distinguished From Artifacts. <i>Journal of Thoracic Oncology</i> , 2020, 15, e118-e120.	1.1	6
124	NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2022, 17, 793-805.	1.1	6
125	The Newly Described Filigree Pattern Is an Expansion of the Micropapillary Adenocarcinoma Concept Rather Than a Proposed New Subtype. <i>Journal of Thoracic Oncology</i> , 2020, 15, e121-e124.	1.1	5
126	Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?. <i>Lung Cancer</i> , 2021, 153, 158-164.	2.0	4

#	ARTICLE	IF	CITATIONS
127	Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3. <i>Human Pathology</i> , 2022, 127, 102-111.	2.0	4
128	Commentary on Testing of Non-Adenocarcinomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 798-798.	2.5	2
129	“Napoleon Hat” Sign: A Distinctive Cytologic Clue to Reactive Pneumocytes. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 443-445.	2.5	2
130	Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8556-8556.	1.6	2
131	Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e81-e83.	2.6	1
132	Type A thymoma presenting with bone metastasis. <i>Histopathology</i> , 2018, 73, 701-703.	2.9	1
133	Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7518-7518.	1.6	1
134	Molecular subtypes and clinical outcomes to initial systemic treatment in patients with small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9018-9018.	1.6	1
135	Clinical outcomes of immune checkpoint inhibitors in <i>HER2</i> -amplified non-small cell lung cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21098-e21098.	1.6	1
136	Molecular Assessment of Multiple Pulmonary Carcinomas: An Evolving Area. <i>Journal of Thoracic Oncology</i> , 2016, 11, e54.	1.1	0
137	Immunostains: Solid Tumors. , 2019, , 23-48.		0
138	Grading (and Classification) Systems Quick Reference: Solid Tumors. , 2019, , 93-111.		0
139	Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9049-9049.	1.6	0
140	Clinicopathologic characteristics of <i>NRG1</i> fusion-positive cancers: A single-institution study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3129-3129.	1.6	0
141	<i>YES1</i> amplification as a primary driver of lung tumorigenesis and <i>YES1/YAP1</i> amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21591-e21591.	1.6	0
142	Molecular Testing Identifies Ultra-Late Recurrences in Lung Carcinomas: Implications for Clinical Management. <i>Journal of Thoracic Oncology</i> , 2022, 17, e50-e51.	1.1	0
143	AKT inhibition as a therapeutic strategy to constrain histological transdifferentiation in <i>EGFR</i> -mutant lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21166-e21166.	1.6	0